By Express News Service
NEW DELHI: Bharat Biotech has delivered three lakh doses of its nasal Covid-19 vaccine to private hospitals across India, the Hyderabad-based pharma company’s executive chairman Krishna Ella said on Sunday.
iNCOVACC, world’s first intranasal Covid-19 vaccine, was launched on January 26. The vaccine is now on sale CoWIN and priced at I800 for private markets and I325 for the state and Central government.“We dispatched three lakh doses of the nasal vaccine to some hospitals two days ago. Let us see the response. Some countries have approached us for (exporting) nasal vaccines.
We can’t reveal the names. International agencies are looking at it very critically,” Ella, executive chairman of Bharat Biotech, said on the sidelines of an event in which an MoU was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.
He also batted for merging all state drug regulatory bodies with the Central Drugs Standard Control Organisation (CDSCO) to ensure “one quality, one standard” for Indian drugs. His remarks came in the backdrop of a third incident of India-made drugs being linked with reported deaths abroad since last October.
On Friday, Chennai-based Global Pharma Healthcare recalled its eye drops linked to vision loss and death in the US following US Food and Drug Administration (FDA) restricting its imports. The pharma company has also been asked to stop all its productions under the category of ophthalmic preparation.
NEW DELHI: Bharat Biotech has delivered three lakh doses of its nasal Covid-19 vaccine to private hospitals across India, the Hyderabad-based pharma company’s executive chairman Krishna Ella said on Sunday.
iNCOVACC, world’s first intranasal Covid-19 vaccine, was launched on January 26. The vaccine is now on sale CoWIN and priced at I800 for private markets and I325 for the state and Central government.
“We dispatched three lakh doses of the nasal vaccine to some hospitals two days ago. Let us see the response. Some countries have approached us for (exporting) nasal vaccines.
We can’t reveal the names. International agencies are looking at it very critically,” Ella, executive chairman of Bharat Biotech, said on the sidelines of an event in which an MoU was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.
He also batted for merging all state drug regulatory bodies with the Central Drugs Standard Control Organisation (CDSCO) to ensure “one quality, one standard” for Indian drugs. His remarks came in the backdrop of a third incident of India-made drugs being linked with reported deaths abroad since last October.
On Friday, Chennai-based Global Pharma Healthcare recalled its eye drops linked to vision loss and death in the US following US Food and Drug Administration (FDA) restricting its imports. The pharma company has also been asked to stop all its productions under the category of ophthalmic preparation.
